MarketPulse

orelabrutinib

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Zenas Biopharma, Inc.

Zenas BioPharma Extends Runway to 2029 Amid Expanded Pipeline Push

Zenas BioPharma reported $718.5M cash position and Q2 2029 runway while advancing multiple clinical programs including obexelimab toward FDA/EMA submissions.
WXXWYZBIOEMA approvalclinical trial
BenzingaBenzinga··Bamboo Works

InnoCare Pharma Hits Profitability Milestone Ahead of Schedule

InnoCare Pharma achieved 644 million yuan profit in 2025, two years ahead of schedule, driven by product sales and licensing partnerships. Hong Kong-listed shares trade at modest 14x P/S ratio.
ZBIOautoimmune diseasesglobal expansion
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Zenas BioPharma Raises $300M Through Convertible Notes and Stock Offering

Zenas BioPharma prices $300M offering combining $200M convertible notes and 5M common shares to fund obexelimab launch and pipeline advancement.
ZBIOautoimmune diseasesequity offering